Abstract
It has recently been shown that the biological activity of the second generation kinin B1 receptor selective antagonist, desArg10 HOE 140, can be improved by specific amino acid substitutions. Starting from this observation, we undertook a systematic structure-activity relationship study of this antagonist, based on the alanine-scan technique, in order to obtain useful information for the rational design of more analogues. Our data indicate that the sequence of desArg10 HOE 140 does not tolerate the replacement by Ala of most of its residues, with the exception of Ser in position 7 and, to a lesser extent, D-Arg in position 1 and Hyp in position 4. The most critical residues appear to be Pro in position 3 and the C-terminal dipeptide DTic-Oic; Ala replacement at these positions resultes in a total loss of activity. Moreover, replacement by Ala of Gly in position 5 reverts the activity of desArg10 HOE 140 to that of an agonist.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bhoola, K.A., Figueroa, C.D. and Worthy, K., Pharmacol. Rev., 44 (1992) 1.
Regoli, D. and Barabè, J., Pharmacol. Rev., 32 (1980) 1.
Hess, J.F. In Farmer, S.G. (Ed.) The Kinin System, Academic Press, London, U.K., 1997, pp. 45–55.
Regoli, D., Barabè, J. and Park, W.K., Can. J. Physiol. Pharmacol., 55 (1977) 855.
Gobeil, F., Pheng, L.H., Badini, I., Nguyen-Le, X.K., Pizard, A., Rizzi, A., Blouin, D. and Regoli, D., Br. J. Pharmacol., 118 (1996) 289.
Gobeil, F., Neugebauer, W., Filteau, C., Jukic, D., Nsa Allogho, S., Pheng, L.H., Nguen-Le, X.K., Bloiun, D. and Regoli, D., Hypertension, 28 (1995) 833.
Hock, F.G., Wirth, K., Albus, U., Linz, W., Gerhards, H.J., Wiemer, G., Henke, S., Breipohl, G., Konig, W., Knolle, J. and Scholkens, B.A., Br. J. Pharmacol., 102 (1991) 769.
Wirth, K., Breipohl, G., Stechl, J., Knolle, J., Henke, S. and Scholkens, B., Eur. J. Pharmacol., 205 (1991) 217.
Stewart, J.M., Gera, L., Hanson, W., Zuzack, J.S., Burkard, M., McCullough, R. and Whalley, E.T., Immunopharmacol., 33 (1996) 51.
Hanson, W.L., McCullough, R.G., Selig, W.M., Wieczorek, M., Ross, S., Whalley, E.T., Stewart, J.M. and Gera, L., Immunopharmacol., 33 (1996) 191.
Marshall, R.G., Tetrahedron, 49 (1993) 3547.
Rovero, P., Viganò, S., Pegoraro, S. and Quartara, L., Lett. Pept. Sci., 2 (1995) 319.
Barlos, K., Chatzi, O., Gatos, D. and Stavropoulos, G., Int. J. Pept. Protein. Res., 37 (1991) 513.
Meini, S., Lecci, A. and Maggi, C.A., Br. J. Pharmacol., 117 (1996) 1619.
Stewart, J.M. and Young, J.D., Solid Phase Peptide Synthesis, 2nd edn., Pierce Chemical Company, Rockford, IL, USA, 1984, pp. 30–31.
Rapp, W., In Schneider, C.H. and Eberle, A.N. (Eds.), Peptides 1992, ESCOM, Leiden, 1993, pp. 243–244.
Akaji, K., Kiso, Y. and Carpino, L.A., J. Chem. Soc. Chem. Commun., (1990) 584.
Steinauer, R. and White, P., In Epton, R. (Ed.), Innovation and Perspectives in Solid Phase Synthesis, Mayflower Worldwide Ltd., Birmingham, UK, 1993, pp. 689–692.
Barlos, K., Gatos, D., Kallitsis, J., Papaphotiu, G., Sotiriu, P., Wenqing, Y. and Schäfer, W., Tetrahedron Lett., 30 (1989) 3943.
Barlos, K., Gatos, D., Kapolos, S., Papaphotiu, G., Schäfer, W. and Wenquing, Y., Tetrahedron Lett., 30 (1989) 3947.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Galoppini, C., Patacchini, R., Meini, S. et al. A structure-activity study on the bradykinin B1 antagonist desArg10-HOE 140: The alanine scan. Letters in Peptide Science 6, 123–127 (1999). https://doi.org/10.1023/A:1008828104465
Issue Date:
DOI: https://doi.org/10.1023/A:1008828104465